North Carolina Macular Dystrophy Is Caused by Dysregulation of the Retinal Transcription Factor PRDM13  by Small, Kent W. et al.
North Carolina Macular Dystrophy Is Caused
by Dysregulation of the Retinal Transcription
Factor PRDM13
Kent W. Small, MD,1 Adam P. DeLuca, PhD,2 S. Scott Whitmore, PhD,2 Thomas Rosenberg, MD,3
Rosemary Silva-Garcia, MD,1 Nitin Udar, PhD,1 Bernard Puech, MD,4 Charles A. Garcia, MD,5
Thomas A. Rice, MD,6 Gerald A. Fishman, MD,7 Elise Héon, MD,8 James C. Folk, MD,2 Luan M. Streb, BA,2
Christine M. Haas, BA,2 Luke A. Wiley, PhD,2 Todd E. Scheetz, PhD,2 John H. Fingert, MD, PhD,2
Robert F. Mullins, PhD,2 Budd A. Tucker, PhD,2 Edwin M. Stone, MD, PhD2
Purpose: To identify speciﬁc mutations causing North Carolina macular dystrophy (NCMD).
Design: Whole-genome sequencing coupled with reverse transcription polymerase chain reaction (RT-PCR)
analysis of gene expression in human retinal cells.
Participants: A total of 141 members of 12 families with NCMD and 261 unrelated control individuals.
Methods: Genome sequencing was performed on 8 affected individuals from 3 families affected with chro-
mosome6elinkedNCMD (MCDR1) and2 individuals affectedwith chromosome5elinkedNCMD (MCDR3). Variants
observed in the MCDR1 locus with frequencies <1% in published databases were conﬁrmed using Sanger
sequencing. Conﬁrmed variants absent from all published databases were sought in 8 additional MCDR1 families
and 261 controls. The RT-PCR analysis of selected genes was performed in stem cellederived human retinal cells.
Main Outcome Measures: Co-segregation of rare genetic variants with disease phenotype.
Results: Five sequenced individuals with MCDR1-linked NCMD shared a haplotype of 14 rare variants
spanning 1 Mb of the disease-causing allele. One of these variants (V1) was absent from all published databases
and all 261 controls, but was found in 5 additional NCMD kindreds. This variant lies in a DNase 1 hypersensitivity
site (DHS) upstream of both the PRDM13 and CCNC genes. Sanger sequencing of 1 kb centered on V1 was
performed in the remaining 4 NCMD probands, and 2 additional novel single nucleotide variants (V2 in 3 families
and V3 in 1 family) were identiﬁed in the DHS within 134 bp of the location of V1. A complete duplication of the
PRDM13 gene was also discovered in a single family (V4). The RT-PCR analysis of PRDM13 expression in
developing retinal cells revealed marked developmental regulation. Next-generation sequencing of 2 individuals
with MCDR3-linked NCMD revealed a 900-kb duplication that included the entire IRX1 gene (V5). The 5 mutations
V1 to V5 segregated perfectly in the 102 affected and 39 unaffected members of the 12 NCMD families.
Conclusions: We identiﬁed 5 rare mutations, each capable of arresting human macular development. Four of
these strongly implicate the involvement of PRDM13 in macular development, whereas the pathophysiologic
mechanism of the ﬁfth remains unknown but may involve the developmental dysregulation of
IRX1. Ophthalmology 2016;123:9-18 ª 2016 by the American Academy of Ophthalmology. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
See Editorial on page 2.
Supplemental material is available at www.aaojournal.org.Few tissues in the human body are as important to the well-
being of a person as the central 3 mm of the human retina.
The ability to drive a car, recognize friends in public, and
see words on a computer, cell phone or printed page are just
a few of the many activities of daily living that depend
heavily on the normal function of the macula.
For all but a few people, the macula functions very well
for the ﬁrst 6 or 7 decades of life, but in older individuals,
the macula is prone to a genetically and mechanistically
diverse group of disorders that are known collectively as age-
related macular degeneration (AMD). For many years, the 2016 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.neovascular complications of AMD were the most common
cause of irreversible blindness in developed countries.1e4
However, the recent advent of antievascular endothelial
growth factor drugs5e8 has dramatically reduced vision loss
from neovascularization, thereby increasing the fraction of
blindness caused by geographic atrophy of the macula.
There are at least 2 approaches that one could envision for
reducing the burden of blindness caused by geographic atrophy
of the macula. The ﬁrst would be to understand the patho-
physiologic mechanisms of AMD in sufﬁcient detail that one
could detect the disease at a very early stage, perhaps even as an9http://dx.doi.org/10.1016/j.ophtha.2015.10.006
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Ophthalmology Volume 123, Number 1, January 2016asymptomatic genetic predisposition, and deliver a safe and
effective preventive therapy to those at risk, much as statins are
now used to reduce the risk of heart disease. Another strategy
would be to rebuild an injured macula with new stem
cellederived retinal cells.9,10 Molecular genetics will play an
important role in both of these approaches.
In the 1990s, scientists sought the genetic causes of several
Mendelian forms of human macular disease for at least 2 rea-
sons. First, it was possible that mild mutations in the genes
responsible for these early-onset conditions might prove to be
responsible for a signiﬁcant subset of the age-related forms of
the disease. Second, it was thought that by discovering how
relatively minor alterations of individual genes could cause
clinical ﬁndings similar to AMD, one would gain valuable
insight into the normal function of the macula. Twenty years
later, it is clear that none of the genes that cause the classic
Mendelian macular dystrophies cause a signiﬁcant fraction of
the late-onset disease, and none of the genes that have been
shown to predispose people to typical AMD cause any mean-
ingful fraction of early-onset Mendelian macular disease.
The ﬁrst of the classic macular dystrophies to have its gene
mapped to a chromosome,11 North Carolina macular dystrophy
(NCMD), is the last to have its speciﬁc disease-causing muta-
tions identiﬁed. The reason for this delaydthe unusual devel-
opmental mechanism of this diseasedmay ultimately make
NCMD themost relevant of theMendelianmacular dystrophies
to the treatment of AMD. North Carolina macular dystrophy
was ﬁrst described in a large kindred from North Carolina by
Leﬂer et al12 and later described in more detail by Frank et al.13
The cross-sectional nature of these studies led the investigators
to believe that the disease was slowly progressive. However,
Small14 reexamined the original Leﬂer kindred approximately
20 years later and realized that NCMD is in fact a
nonprogressive developmental disorder with widely variable
expressivity.
In the decades since the MCDR1 locus was mapped, many
additional families with NCMD have been described,15e20
including 2 families that link to a separate locus on chromo-
some 5 (MCDR3).21,22 The critical region on chromosome 6
has been considerably narrowed,23,24 and all of the coding re-
gions of genes within this interval have been exhaustively
studied by us and other investigators.25 The failure of these
experiments to identify plausible disease-causing mutations in
any of these kindreds suggested that the mutations were likely
to exist in nonexomic DNA and to affect the expression of a
nearby gene or genes rather than the structure of its gene
product. The purpose of this study was to take advantage of
recent advances in whole-genome sequencing to comprehen-
sively screen the nonexomic sequences within theMCDR1 and
MCDR3 loci to identify disease-causing mutations in families
affected with these diseases.Methods
Human Subjects
All subjects provided written informed consent for this research
study, which was approved by the institutional review board of
the University of Iowa and adhered to the tenets set forth in
the Declaration of Helsinki. Blood samples were obtained from10all subjects, and DNA was extracted using a nonorganic protocol,
as previously described.26
Next-Generation Sequencing of MCDR1 Patients
A targeted genome capture of the linked region was performed on
3 members of family A (2 affected and 1 unaffected), 2 members
of family K, and 1 member of family B. Libraries prepared from
these captures were sequenced on an Illumina HiSeq. In addition,
30 whole genomes were obtained from 5 affected individuals:
2 from family A, 1 from family K, and 2 from family L. These
libraries were sequenced on an Illumina HiSeqX. All of these
individuals are noted in blue in Supplemental Figure 1 (available at
www.aaojournal.org).
Bioinformatic Analysis of Next-Generation
Sequencing Data
Sequences were analyzed as described previously.27 Brieﬂy,
sequences were aligned to the reference genome using BWA-mem,
and single nucleotide variants and small insertions/deletions were
identiﬁed using a GATK-based pipeline.28,29 Variants mapping
outside the MCDR1-linked region and those found at a frequency of
1% or greater in public databases30e32 were removed. Variants were
then ﬁltered, requiring that all affected individuals with a given
haplotype share the heterozygous variant; all other individuals did not
share the variant.
Copy number variants were investigated using Pindel and manual
inspection of the aligned sequence data using the Integrative Genome
Viewer.33,34 As a control, the identiﬁed genes were screened for copy
number variants using Conifer35 in an internal database of 953 whole
exomes of patients with eye disease.
Conﬁrmation of Whole-Genome Sequencing
Variants identiﬁed by whole-genome sequencing were conﬁrmed
using automated bidirectional DNA sequencing with dye termi-
nation chemistry on an ABI 3730 sequencer (ThermoFisher Sci-
entiﬁc, Foster City, CA).
Screening of Control Subjects
A total of 261 normal control subjects were screened for the presence
of V1 to V3 (Table 1) using unidirectional automated DNA
sequencing. To evaluate these controls for the presence of V4 and
V5 (Table 1), oligonucleotide primers were designed to amplify
across the novel junctions created by these tandem duplications
(Supplemental Table 1, available at www.aaojournal.org), and the
products of these ampliﬁcations were evaluated by electrophoresis
on 6% nondenaturing polyacrylamide gels followed by silver
staining, as previously described.36
Induced Pluripotent Stem Cell Generation and 3-
Dimensional Differentiation. Human dermal ﬁbroblasts were iso-
lated from skin biopsies obtained from normal individuals after
informed consent. Cultured ﬁbroblasts were reprogrammed via viral
transduction of the transcription factors OCT4, SOX2, KLF4, and
c-MYC, as previously described.27,37,38 Human induced pluripotent
stem cells (iPSCs) were maintained in Essential 8 media (Life Tech-
nologies, Carlsbad, CA) on Laminin 521ecoated plates (Corning Life
Sciences, Tewksbury, MA). To initiate differentiation, iPSCs were
removed from the culture substrate via incubation with TrypLE
Express Enzyme (Life Technologies) dissociated into a single cell
suspension and subsequently differentiated via the 3-dimensional (3D)
differentiation protocol previously published by Eiraku et al.39
RNA Isolation and Reverse Transcription Polymerase Chain
Reaction. Total RNA was extracted from normal human iPSCs
isolated at 0, 30, 60, and 100 days after differentiation using the
















A 76511e14,24,40e45 North Carolina V1 chr6:100040906 G>T 51 22 73
B 70245 North Carolina V1 chr6:100040906 G>T 4 5 9
C 76817,24,45 North Carolina V1 chr6:100040906 G>T 1 1 2
D 77224,45 North Carolina V1 chr6:100040906 G>T 4 0 4
E 119324,45 North Carolina V1 chr6:100040906 G>T 3 0 3
F 129224,45 N/A V1 chr6:100040906 G>T 2 1 3
G 76916,24,45 French V2 chr6:100040987 G>C 1 0 1
H 71845 N/A V2 chr6:100040987 G>C 1 0 1
I 1574 N/A V2 chr6:100040987 G>C 11 5 16
J 70945 N/A V3 chr6:100041040 C>T 2 0 2
K 146319,45 Belize V4 chr6:100020205-100143306 123101 bp tandem duplication 11 4 15
L MCDR322 Danish V5 chr5:3587901-4486027 898126 bp tandem duplication 11 1 12
102 39 141
bp ¼ base pairs; N/A ¼ not available.
Small et al  North Carolina Macular DystrophyRNeasy Mini-kit (Qiagen, Germantown, MD), per the manufac-
turer’s instructions, and 100 ng of RNA was ampliﬁed via
SuperScript III One-Step RT-PCR System with Platinum Taq
DNA Polymerase (Life Technologies) using the gene-speciﬁc
primers described in Supplemental Table 1 (available at
www.aaojournal.org).
Immunocytochemistry of 3-Dimensional Induced Pluripotent
Stem CelleDerived Eyecups. Three-dimensional iPSC-derived
eyecups were embedded in 4% agarose, sectioned at a thick-
ness of 100 mm using a Leica VT1000 S vibratome (Leica
Microsystems, Wetzlar, Germany) and labeled with primary
antibodies targeted against mouse anti-SOX2 (#MAB2018;
1:1000; R&D Systems, Minneapolis, MN), rabbit anti-PAX6
(#901301; 1:1000; BioLegend, San Diego, CA), goat anti-
biotinylated-OTX2 (#BAF1979; 1:500; R&D Systems), rabbit
anti-Ki67 (#ab15580; 1:500; Abcam, Cambridge, MA), rabbit
anti-TUJ1 (#T2200; 1:500; Sigma-Aldrich, St. Louis, MO),
goat anti-biotinylated-NRL (#BAF2945; 1:500; R&D Sys-
tems), mouse anti-HuC/D (#A-21271; 1:500; Thermo Fisher
Scientiﬁc, Waltham, MA), and rabbit anti-recoverin (#AB5585;
1:2000; EMD Millipore, Billerica, MA). To detect F-actin,
eyecups were stained with Alexa Fluor 488 Phalloidin
(#A12379; 1:500; Life Technologies). Primary antibodies were
detected using ﬂuorescently conjugated Alexa Fluor secondary
antibodies (Life Technologies). Cell nuclei were counterstained
using 4’6-diamidino-2-phyenylindole. Sectioned eyecups were
imaged using a Leica DM 2500 SPE confocal microscope
(Leica Microsystems, Wetzler, Germany).Results
Twelve families manifesting the clinical features of NCMD were
studied, all but 1 of whom have been described else-
where.11e14,16,17,19,24,40e44 Six of these families share a haplotype
of short tandem-repeat polymorphisms in the MCDR1 locus on
chromosome 6, suggestive of a common founder,45 whereas 5 others
have been linked to MCDR1 but exhibit a different marker haplotype.
The remaining family has been linked to the MCDR3 locus
on chromosome 5.22 DNA samples from 102 affected and 39
unaffected members of these families were available for this
study. The family structures and speciﬁc individuals included inthis study are shown in Supplemental Figure 1 (available at
www.aaojournal.org).
Subject 7043 in family A has been observed by us for more
than 30 years43 and is an excellent example of the cardinal clinical
features of NCMD. She was ﬁrst seen at 2 years and 9 months of
age and displayed a visual acuity of 20/40 in the right eye and 20/
60 in the left eye with line pictures. Fundus examination revealed
small areas of atrophy surrounded by drusen-like deposits in both
eyes. A prism cover test revealed unmaintained ﬁxation in the left
eye, and a trial of part-time occlusion was begun. Two months
later, her vision had improved to 20/40 in both eyes, and patching
was discontinued. At age 6 years, her acuity had decreased slightly
to 20/50 in both eyes. Two small red dots suggestive of hemor-
rhage were observed on the nasal edge of the atrophy in the left eye
(Fig 1A, B), but ﬂuorescein angiography revealed no evidence of
active neovascularization at that visit (Fig 1C, D and
Supplemental Fig 2, available at www.aaojournal.org). At age 8
years, her acuity remained 20/50 in both eyes and a new
subretinal ﬁbrotic scar was noted in the left eye, extending from
1 o’clock to 7 o’clock around the central patch of atrophy (Fig
1E). Two years later, the acuity and fundus appearance were
unchanged (Fig 1F), but the following year, at age 11 years, the
scar in the left eye had extended another 3 clock hours (Fig 1G)
with little change in acuity (20/50-2). When last seen at age 33
years, her visual acuity was 20/60-1 in the right eye and 20/70-1
in the left eye. The fundus appearance (Fig 1H) was similar to
that at her visit 22 years earlier. Optical coherence tomography
of the left eye revealed an abrupt termination of the
photoreceptors, retinal pigment epithelium, and choroid at the 1
edge of the atrophic lesion that was not distorted by the ﬁbrotic
scar (Fig 1I).
The original linkage of the NCMD phenotype to chromosome 6q11
and the subsequent narrowing of the MCDR1 interval24 depended
heavily on families A and J. Detailed genotyping of additional
members of these families revealed an unaffected recombinant
individual (Supplemental Fig 1K, available at www.aaojournal.org)
that narrowed the centromeric end of the interval to the genetic
marker D6S1717 (Fig 2). A genomic fragment capture of the
narrowed disease interval and next-generation sequencing were then
performed in 1 unaffected and 2 affected members of family A.
However, only 85% of the nucleotides in the disease interval were
successfully sequenced in this experiment, and therefore 2 additional11
Figure 1. Retinal images spanning 30 years from the left eye of an affected
member of family A: color fundus photograph (A), red-free fundus
photograph (B), early-phase ﬂuorescein angiogram (C), and late-phase
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12affected members of the same family were subjected to whole-genome
sequencing. Analysis of the sequence data from these 4 affected
individuals (noted in blue in Supplemental Fig 1A, available at
www.aaojournal.org) revealed a haplotype of 14 rare variants that
spanned 1 Mb of the disease-causing allele (Fig 2). One of these
variants (V1; Table 1) was absent from all published databases and
261 normal controls, but was found in all affected members of 5 of
10 additional NCMD kindreds (families BeF; Supplemental Fig 1,
available at www.aaojournal.org) that were known or suspected to
map to MCDR1. This variant lies in a DNase 1 hypersensitivity site
(DHS) upstream of both the PRDM13 and CCNC genes (Fig 2).
Sanger sequencing of 1000 base pairs (bp) centered on V1 was
performed in the probands of the remaining 5 NCMD families, and
2 additional novel single nucleotide variants (V2 in families
GeI and V3 in family J; Table 1; Supplemental Fig 1, available
at www.aaojournal.org) were identiﬁed within 134 bp of the
location of V1 (Fig 2). Whole-genome sequencing of an
affected individual from the remaining MCDR1 family (family
K; Supplemental Fig 1, available at www.aaojournal.org) was
performed, and a 123-kb tandem duplication (V4; Table 1)
containing the entire coding sequence of PRDM13 was
identiﬁed (Fig 2 and Supplemental Fig 3A, available at
www.aaojournal.org). Collectively, V1 to V4 were present in 91
of 91 affected members of these 11 families, absent from 38 of
38 unaffected members, and absent from 261 unrelated control
individuals (522 chromosomes). In addition, a review of
the Database of Genome Variants46 revealed no instances of
duplication of the entire PRDM13 coding sequence in normal
individuals.
To determine whether PRDM13 and CCNC are expressed during
retinal development, iPSCs were used to generate retinal tissue via
3D differentiation. After 30 days of differentiation (D30), 3D iPSC-
derived eyecup-like structures are polarized with highly organized
ﬁlamentous actin (F-actin) networks composed of actively proliferating
Ki67-positive cells (Fig 3A). At this stage of development, 3D eyecups
predominantly contain cells that express early retinal-speciﬁc markers:
SOX2, PAX6, andOTX2 (Fig 3B). PAX6, amaster regulator of retinal
development, is expressed throughout the eyecup and helps to drive the
expression of the photoreceptor precursor cell-speciﬁc transcription
factor OTX2. PAX6 and OTX2 are co-expressed in most cells at this
stage of development (Fig 3B). After 60 days of differentiation, PAX6
expression becomes restricted to presumptive retinal pigment
epithelium cells, and pockets of presumptive photoreceptor cells that
express OTX2 independent of PAX6 arise (Fig 3C). After 100 days
of differentiation, 3D eyecups are laminated with an inner layer
containing retinal neurons that express the ganglion cellespeciﬁc
marker HuC/D and an outer layer containing photoreceptor cells that
robustly express the phototransduction protein recoverin (Fig 3D).
Analysis of RNA isolated from iPSCs at 0, 30, 60, and 100 days
after differentiation revealed that expression of PRDM13 is
negatively correlated with retinal development (Fig 4). Speciﬁcally,
as cells progress from a pluripotent stem cell state to mature retinal
neurons, PRDM13 transcript is downregulated. Of note, CCNC is
consistently expressed across all developmental time points (Fig 4).
In 2010, Rosenberg et al22 mapped the disease-causing muta-
tion of a Danish kindred (family L; Supplemental Fig 1, available
at www.aaojournal.org) with an NCMD phenotype to an 8-cM
interval on chromosome 5 (MCDR3) (Fig 5A) that had beenﬂuorescein angiogram (D) at age 6 years; color fundus photographs at
ages 8 years (E), 10 years (F), 11 years (G), and 33 years (H); optical
coherence tomogram at age 33 years (I). This patient has been reported
(Table 1). Stereo images of BeD are provided in Supplemental Figure 2
(available at www.aaojournal.org).
Figure 2. Discovery of North Carolina macular dystrophy (NCMD)e
causing variants in MCDR1. The critical region of MCDR1 was narrowed
to 883 kb by a single, unaffected recombinant individual (recombinant
denoted by asterisks here and in Supplemental Fig 1J, asterisk, available at
www.aaojournal.org). Genome sequencing revealed 14 rare variants (violet
vertical bars) across this region, 1 of which (V1) has never been observed
in normal individuals. This novel variant falls within a DNase
hypersensitivity site (pink) upstream of the PRDM13 gene (green) that
was later found to include other rare variants in NCMD families (V2
and V3). In addition, a 123-kb tandem duplication containing the
PRDM13 gene (yellow, V4) was discovered in 1 NCMD family. bp ¼
base pairs.
Small et al  North Carolina Macular Dystrophypreviously identiﬁed by Michaelides et al.21 We performed
whole-genome sequencing of 2 affected individuals in this family
and identiﬁed a 900-kb tandem duplication (V5) (Table 1) that
included the entire coding sequence of IRX1 (Fig 5A and
Supplemental Fig 3B, available at www.aaojournal.org). This
duplication was present in all 11 affected members of the family,
absent from 1 unaffected member, absent from the Database of
Genome Variants,46 and absent from 261 unrelated controls.
However, some smaller duplications that include in some cases
the entire coding sequence of IRX1 have been observed in
normal individuals,46 suggesting that the disease-causing element
in this large duplication is not the IRX1 coding sequence itself.
Also, unlike PRDM13 (Fig 3D), reverse transcription polymerase
chain reaction analysis of IRX1 in normal iPSC-derived human
retinal cells revealed no variation in expression in the ﬁrst 100 days
of development (Fig 5B).Discussion
The technologic advancements that have occurred in the
ﬁeld of human genomics since the NCMD locus on chro-
mosome 6 was ﬁrst identiﬁed11 have been breathtaking. Few
investigators who studied inherited eye diseases in the
1990s would have imagined that in less than 25 years,
whole-genome sequencing of individual patients would be
so commonplace that the sequence of thousands of
unrelated individuals would be freely available in public
databases30e32 and that the President of the United States
would launch a precision medicine initiative based on thesenew molecular capabilities and data.47 However, the most
valuable data in both the original linkage study and the
present study were not molecular; the most valuable data
were the detailed clinical observations that allowed several
families with a rare and unusual phenotype to be correctly
separated from thousands of other members of hundreds
of other families with similar diseases caused by genes at
other loci.
Although counterintuitive to many people, it is a fact that
as genomic tools become more powerful and less expensive,
accurate and detailed clinical information become more
necessary for the correct interpretation of the resulting
molecular data. There are both quantitative and qualitative
reasons for this. Now that tens of thousands of genes can be
assessed in a single patient, there are tens of thousands of
additional opportunities to observe a plausible disease-
causing variant by chance than if one investigated only a
single gene. By using clinical data to focus the hypothesis to
just a few genes, one can overcome the large multiple
measurements problem inherent in whole-genome data.
The qualitative reason that molecular data have become
more difﬁcult to interpret as they have become easier and less
expensive to acquire is embodied in the difference between the
coding and noncoding portions of genes. Coding sequences
exist in groups of 3 nucleotides, known as codons, that each
specify a single amino acid in the resulting proteins. The
universality of the genetic code allows one to predict
the structural effect of a given coding sequence mutation on
the resulting protein with greater accuracy than one could if the
same mutation occurred in the noncoding portion of a gene,
where its effect would be tempered by the actions of DNA
binding proteins, DNA methylation, noncoding RNA mole-
cules, the proximity to coding sequences, and other factors that
are incompletely understood at the present time.
There are 10 genes in the MCDR1 locus, and individuals
from multiple unrelated kindreds affected with MCDR1-linked
NCMD have been extensively screened for mutations in the
coding sequences of these genes, with no plausible disease-
causing variants identiﬁed. Therefore, we expected that
NCMD-causing mutations would eventually be found in the
noncoding portions of the MCDR1 locus, and we took
advantage of 2 valuable resources and 1 genetic fact to detect
these mutations among the many functionally neutral poly-
morphisms that exist in the noncoding sequences of all in-
dividuals: (1) multiple unrelated families exhibiting a classic
NCMD phenotype, (2) public genome databases with se-
quences of thousands of individuals,30e32 and (3) the fact that
mutations that cause high-penetrance autosomal-dominant
diseases should be no more common in the general population
than the disease itself.
The data supporting the pathogenicity of V1eV4 are
compelling. In family A, the original NCMD family and the
largest one ascertained to date, V1 is the only nucleotide in the
883-kb MCDR1 locus that is absent from all public databases
and therefore of similar population frequency to NCMD itself.
This variant lies in a 255-bp region of DNase I hypersensitivity
that is upstream of a gene encoding a retinal transcription
factor, PRDM13. It is noteworthy that PRDM13 is the only
gene in the MCDR1 critical region that is solely expressed in
the neural retina.48,49 DNase I hypersensitivity is an indicator13
Figure 3. Using normal human induced pluripotent stem cells (iPSCs) to model retinal development. AeD, Immunocytochemical analysis of iPSC-derived
eyecup-like structures targeted against F-actin, SOX2, PAX6, OTX2, HuC/D, and recoverin (RCVRN). After 30 days of differentiation (D30), polarized
neural epithelia (A, F-Actin in green) composed of proliferating cells (A, Ki67 in red) that are positive for the early retinal progenitor cell markers SOX2 (B,
green), PAX6 (B, red), and OTX2 (B, white) are present. After 60 days of differentiation (D60), PAX6 (C, red) expression is restricted to OTX2-negative
presumptive retinal pigment epithelium, whereas OTX2 (C, white) is restricted to PAX6-negative photoreceptor precursor cells. After 100 days of differ-
entiation (D100), eyecups are laminated with HuC/D-positive (D, green) ganglion cellelike neurons in the inner layer and recoverin-positive (D, red)
photoreceptor precursor cells in the outer layer. Insets depict individual ﬂuorescent channels. A and C, 20 magniﬁcation. B and D, 40 magniﬁcation.
DAPI ¼ 4’6-diamidino-2-phyenylindole.
Ophthalmology Volume 123, Number 1, January 2016of chromatin accessibility that is often associated with tran-
scription factor binding sites.50 V1 was later found in 5
independently ascertained NCMD kindreds, shown to
segregate perfectly among 65 affected and 29 unaffected
members of these 6 families, and shown to be absent from14261 unrelated individuals ascertained in Iowa. The latter
individuals were sequenced just to make sure that there
was not an artifactual gap in the public genome data.
Conventional sequencing of this DHS in 5 V1-negative
NCMD families revealed that 4 harbored point
Figure 4. Retinal expression of PRDM13 is developmentally regulated.
Reverse transcription polymerase chain reaction analysis of induced
pluripotent stem cells (iPSCs) after 0, 30, 60, and 100 days of retinal dif-
ferentiation (D0, D30, D60, and D100, respectively) using primers targeted
against the retinal lineage markers PAX6, s-Opsin, and Rhodopsin, and genes
within the MCDR1 locus, PRDM13 and CCNC. As iPSCs progress from a
pluripotent state to immature PAX6-expressing retinal progenitor cells to
mature s-Opsineexpressing cone and rhodopsin-expressing rod photore-
ceptor cells, PRDM13 expression decreases (PRDM13 iPSC-L1, iPSC-L2,
and iPSC-L3). iPSC-L1 ¼ control iPSC line 1; iPSC-L2 ¼ control iPSC
line 2; iPSC-L3 ¼ control iPSC line 3.
Figure 5. Discovery of the North Carolina macular dystrophyecausing
variant in MCDR3. A, By using whole-genome sequencing, a 900-kb
duplication (yellow, V5) containing the gene IRX1 (green) was found in a
family mapped to MCDR3. B, Reverse transcription polymerase chain
reaction of developing induced pluripotent stem cellederived photore-
ceptor precursor cells revealed that unlike PRDM13, IRX1 expression is
consistent across all developmental time points tested.
Small et al  North Carolina Macular Dystrophymutations (V2 and V3) within 134 bp of V1. Whole-
genome sequencing of the ﬁfth V1-negative family
revealed a tandem duplication containing the DHS and the
entire coding sequence of PRDM13 (V4). V2 to V4 were
found to segregate perfectly among the 26 affected and 9
unaffected members of these 5 families and were absent from
all public databases and the 261 control individuals from Iowa.
Although the association between these variants and the
disease phenotype is extraordinarily strong (P < 1029, by
Fisher exact test), the mechanism by which they cause
disease is far from established. For example, the gene
CCNC, which encodes a ubiquitous cell cycle controller,
lies in the opposite orientation of PRDM13 on the opposite
side of the DHS and thus could, in principle, also be affected
by these mutations and therefore be involved in the patho-
genesis of NCMD. One argument against CNCC as anNCMD gene, in addition to its ubiquitous expression, is the
conﬁguration of the DHSs in the tandem duplication of
family K. The entire coding region of PRDM13 is dupli-
cated in this mutation, and both DHSs are immediately
adjacent to a PRDM13 gene. In contrast, only 1 of the DHSs
is adjacent to the unduplicated CCNC gene (Supplemental
Fig 4, available at www.aaojournal.org).
The observation that NCMD is a developmental abnormality
is also consistent with PRDM13 being the responsible gene.
PRDM13 is a member of a large family of “helix-loop-helix”
DNA-binding proteins that play key roles in controlling gene
expression during development.51 Because the formation of the
macula is accompanied by differential expression of an array of
genes involved in axon guidance and inhibition of
angiogenesis,52 this process likely relies on a precise
interaction between transcription factors (like PRDM13) and
their target genes. Thus, a change in the abundance of a
transcription factor due to mutations in its own regulatory
regions could plausibly lead to impaired cell fate
speciﬁcations in the developing macula. Therefore, it is
notable that both PRDM13 and IRX1 are proteins with
important roles in regulating gene expression.
One of the great advantages of iPSCs is their ability to
differentiate ex vivo into any cell type of the 3 embryonic
germ layers. For many organ systems, iPSC differentiation
faithfully recapitulates the various cell fate decisions made
during embryonic development.39,53e56 Being able to obtain
embryonic tissue from adult somatic cells affords researchers
with the ability to determine if and when in cellular develop-
ment speciﬁc genes are expressed. In this study, human iPSC-
derived retinal tissue was used to demonstrate that PRDM13 is
developmentally regulated while other genes in the MCDR1
locus (i.e., CCNC) are not. To demonstrate this ﬁnding in the
absence of the pluripotent stem cell technology, one would
have to obtain retinal tissue from human fetuses at different
points in development, an approach that would be logistically
difﬁcult and raise serious ethical concerns. The capability of
iPSCs to generate otherwise inaccessible tissues such as the
retina also gives researchers the ability to investigate the
pathophysiologic effect of newly identiﬁed gene defects on
cell health and function. This will be especially useful in the15
Ophthalmology Volume 123, Number 1, January 2016modern gene-sequencing era when trying to determine the
mechanistic effects of noncoding genetic variants such as those
identiﬁed in this study. In future studies, it will be interesting
to generate retinal tissue from patients with each of the mu-
tations described in this study and to determine their effect on
gene expression, as well as cellular differentiation, maturation,
health, and function.
The tandem duplication in the MCDR3 locus is very
likely to be the disease-causing mutation in family L simply
because it is very unlikely that the largest duplication
involving IRX1 currently known to exist among the thou-
sands of currently available human genome sequences46
would occur by chance in the very small portion of the
genome that has been implicated in the disease.21,22 How-
ever, unlike MCDR1, no additional mutations have been
identiﬁed in different MCDR3 families to corroborate this
ﬁnding and to narrow the mechanistic possibilities. Also
unlike MCDR1, where PRDM13 exhibits dramatic expres-
sion differences in the ﬁrst 100 days of retinal development,
IRX1 is constitutively expressed in normal individuals.
Perhaps the large duplication alters the evolutionarily
conserved chromosome conformation of the IRXA gene
cluster.57 Future experiments with retinal cells generated
from patients with NCMD themselves will likely
signiﬁcantly clarify the mechanism of both MCDR loci.
A practical outcome of this work is that one can detect every
mutation reported in this article using only 3 polymerase chain
reactionebased sequencing reactions (Supplemental Table 1,
available at www.aaojournal.org). The availability of a simple
genetic test for this disease will likely result in the diagnosis
of many additional individuals, which not only will allow
physicians to provide more accurate genetic and prognostic
information than was possible before but also will likely
accelerate the discovery of additional disease-causing variants
and additional clinical manifestations of the known mutations.
Both of these will help unravel the precise mechanisms through
which these loci contribute to the formation of the normal
macula.
In conclusion, we identiﬁed 5 rare mutations that each are
capable of arresting the development of the human macula.
Four of these strongly implicate the involvement of the gene
PRDM13 in macular development, whereas the pathophys-
iologic mechanism of the ﬁfth remains unknown but may
involve the developmental dysregulation of IRX1.
Acknowledgments. The authors thank the members of the
families reported in this article for their valuable participation in
this study and Jeaneen Andorf for excellent technical assistance
and proofreading of the manuscript. This work is dedicated to the
memory of our colleague Maurice Rabb, MD.References
1. Friedman DS, O’Colmain BJ, Muñoz B, et al. Prevalence of
age-related macular degeneration in the United States. Arch
Ophthalmol 2004;122:564–72.
2. Klein R, Klein BE, Cruickshanks KJ. The prevalence of age-
related maculopathy by geographic region and ethnicity.
Prog Retin Eye Res 1999;18:371–89.163. Wong TY, Wong T, Chakravarthy U, et al. The natural history
and prognosis of neovascular age-related macular degenera-
tion: a systematic review of the literature and meta-analysis.
Ophthalmology 2008;115:116–26.
4. Wong WL, Su X, Li X, et al. Global prevalence of age-related
macular degeneration and disease burden projection for 2020
and 2040: a systematic review and meta-analysis. Lancet Glob
Health 2014;2:e106–16.
5. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for
neovascular age-related macular degeneration. N Engl J Med
2006;355:1419–31.
6. Rosenfeld PJ, Moshfeghi AA, Puliaﬁto CA. Optical coherence
tomography ﬁndings after an intravitreal injection of bev-
acizumab (Avastin) for neovascular age-related macular
degeneration. Ophthalmic Surg Lasers Imaging 2005;36:
331–5.
7. CATT Research Group, Martin DF, Maguire MG, et al.
Ranibizumab and bevacizumab for neovascular age-
related macular degeneration. N Engl J Med 2011;364:
1897–908.
8. Bressler NM, Doan QV, Varma R, et al. Estimated cases of
legal blindness and visual impairment avoided using ranibi-
zumab for choroidal neovascularization: non-Hispanic white
population in the United States with age-related macular
degeneration. Arch Ophthalmol 2011;129:709–17.
9. Tucker BA, Mullins RF, Streb LM, et al. Patient-speciﬁc
iPSC-derived photoreceptor precursor cells as a means to
investigate retinitis pigmentosa. Elife 2013;2:e00824.
10. Tucker BA, Park IH, Qi SD, et al. Transplantation of adult
mouse iPS cell-derived photoreceptor precursors restores
retinal structure and function in degenerative mice. PLoS One
2011;6:e18992.
11. Small KW, Weber JL, Roses A, et al. North Carolina macular
dystrophy is assigned to chromosome 6. Genomics 1992;13:
681–5.
12. Leﬂer WH, Wadsworth JA, Sidbury JB. Hereditary macular
degeneration and amino-aciduria. Am J Ophthalmol 1971;71:
224–30.
13. Frank HR, Landers MB, Williams RJ, Sidbury JB. A new
dominant progressive foveal dystrophy. Am J Ophthalmol
1974;78:903–16.
14. Small KW. North Carolina macular dystrophy, revisited.
Ophthalmology 1989;96:1747–54.
15. Pauleikhoff D, Sauer CG, Müller CR, et al. Clinical and ge-
netic evidence for autosomal dominant North Carolina macular
dystrophy in a German family. Am J Ophthalmol 1997;124:
412–5.
16. Small KW, Puech B, Mullen L, Yelchits S. North Carolina
macular dystrophy phenotype in France maps to the MCDR1
locus. Mol Vis 1997;3:1.
17. Small KW, Garcia CA, Gallardo G, et al. North Carolina mac-
ular dystrophy (MCDR1) in Texas. Retina 1998;18:448–52.
18. Rohrschneider K, Blankenagel A, Kruse FE, et al. Macular
function testing in a German pedigree with North Carolina
macular dystrophy. Retina 1998;18:453–9.
19. Rabb MF, Mullen L, Yelchits S, et al. A North Carolina
macular dystrophy phenotype in a Belizean family maps to the
MCDR1 locus. Am J Ophthalmol 1998;125:502–8.
20. Reichel MB, Kelsell RE, Fan J, et al. Phenotype of a British
North Carolina macular dystrophy family linked to chromo-
some 6q. Br J Ophthalmol 1998;82:1162–8.
21. Michaelides M, Johnson S, Tekriwal AK, et al. An early-onset
autosomal dominant macular dystrophy (MCDR3) resembling
North Carolina macular dystrophy maps to chromosome 5. Invest
Ophthalmol Vis Sci 2003;44:2178–83.
Small et al  North Carolina Macular Dystrophy22. Rosenberg T, Roos B, Johnsen T, et al. Clinical and genetic
characterization of a Danish family with North Carolina
macular dystrophy. Mol Vis 2010;16:2659–68.
23. Sauer CG, Schworm HD, Ulbig M, et al. An ancestral core
haplotype deﬁnes the critical region harbouring the North
Carolina macular dystrophy gene (MCDR1). J Med Genet
1997;34:961–6.
24. Small KW, Udar N, Yelchits S, et al. North Carolina macular
dystrophy (MCDR1) locus: a ﬁne resolution genetic map and
haplotype analysis. Mol Vis 1999;5:38.
25. Yang Z, Tong Z, Chorich LJ, et al. Clinical characterization
and genetic mapping of North Carolina macular dystrophy.
Vision Res 2008;48:470–7.
26. Braun TA, Mullins RF, Wagner AH, et al. Non-exomic
and synonymous variants in ABCA4 are an important
cause of Stargardt disease. Hum Mol Genet 2013;22:
5136–45.
27. Tucker BA, Scheetz TE, Mullins RF, et al. Exome sequencing
and analysis of induced pluripotent stem cells identify the
cilia-related gene male germ cell-associated kinase (MAK) as a
cause of retinitis pigmentosa. Proc Natl Acad Sci U S A
2011;108:E569–76.
28. Li H, Durbin R. Fast and accurate long-read alignment with
Burrows-Wheeler transform. Bioinformatics 2010;26:589–95.
29. McKenna A, Hanna M, Banks E, et al. The Genome Analysis
Toolkit: a MapReduce framework for analyzing next-
generation DNA sequencing data. Genome Res 2010;20:
1297–303.
30. Exome Aggregation Consortium (ExAC). Available at: http://
exac.broadinstitute.org. Accessed December 9, 2014.
31. Exome Variant Server. NHLBI Exome Sequencing Project (ESP)
Available at: http://evs.gs.washington.edu/EVS/. Accessed June
27, 2012.
32. 1000 Genomes Project Consortium. A map of human genome
variation from population-scale sequencing. Nature 2010;467:
1061–73.
33. Ye K, Schulz MH, Long Q, et al. Pindel: a pattern growth
approach to detect break points of large deletions and medium
sized insertions from paired-end short reads. Bioinformatics
2009;25:2865–71.
34. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative
Genomics Viewer (IGV): high-performance genomics data
visualization and exploration. Brief Bioinform 2013;14:
178–92.
35. Krumm N, Sudmant PH, Ko A, et al. Copy number variation
detection and genotyping from exome sequence data. Genome
Res 2012;22:1525–32.
36. Mykytyn K, Nishimura DY, Searby CC, et al. Identiﬁcation of
the gene (BBS1) most commonly involved in Bardet-Biedl
syndrome, a complex human obesity syndrome. Nat Genet
2002;31:435–8.
37. Tucker BA, Anﬁnson KR, Mullins RF, et al. Use of a synthetic
xeno-free culture substrate for induced pluripotent stem cell
induction and retinal differentiation. Stem Cells Transl Med
2013;2:16–24.
38. Burnight ER, Wiley LA, Drack AV, et al. CEP290 gene
transfer rescues Leber congenital amaurosis cellular pheno-
type. Gene Ther 2014;21:662–72.39. Eiraku M, Takata N, Ishibashi H, et al. Self-organizing optic-
cup morphogenesis in three-dimensional culture. Nature
2011;472:51–6.
40. Fetkenhour CL, Gurney N, Dobbie JG, Choromokos E. Cen-
tral areolar pigment epithelial dystrophy. Am J Ophthalmol
1976;81:745–53.
41. Hermsen VM, Judisch GF. Central areolar pigment epithelial
dystrophy. Ophthalmologica 1984;189:69–72.
42. Small KW, Killian J, McLean WC. North Carolina’s dominant
progressive foveal dystrophy: how progressive is it? Br J
Ophthalmol 1991;75:401–6.
43. Small KW, Hermsen V, Gurney N, et al. North Carolina
macular dystrophy and central areolar pigment epithelial dys-
trophy. One family, one disease. Arch Ophthalmol 1992;110:
515–8.
44. Keithahn MA, Huang M, Keltner JL, et al. The variable ex-
pressivity of a family with central areolar pigment epithelial
dystrophy. Ophthalmology 1996;103:406–15.
45. Small KW. North Carolina macular dystrophy: clinical fea-
tures, genealogy, and genetic linkage analysis. Trans Am
Ophthalmol Soc 1998;96:925–61.
46. MacDonald JR, Ziman R, Yuen RKC, et al. The Database of
Genomic Variants: a curated collection of structural variation
in the human genome. Nucleic Acids Res 2014;42:D986–92.
47. Collins FS, Varmus H. A new initiative on precision medicine.
N Engl J Med 2015;372:793–5.
48. Whitmore SS, Wagner AH, DeLuca AP, et al. Transcriptomic
analysis across nasal, temporal, and macular regions of human
neural retina and RPE/choroid by RNA-Seq. Exp Eye Res
20141–14.
49. Melé M, Ferreira PG, Reverter F, et al. Human genomics. The
human transcriptome across tissues and individuals. Science
2015;348:660–5.
50. Thurman RE, Rynes E, Humbert R, et al. The accessible
chromatin landscape of the human genome. Nature 2012;489:
75–82.
51. Fog CK, Galli GG, Lund AH. PRDM proteins: important players
in differentiation and disease. Bioessays 2012;34:50–60.
52. Kozulin P, Natoli R, O’Brien KMB, et al. Differential
expression of anti-angiogenic factors and guidance genes in
the developing macula. Mol Vis 2009;15:45–59.
53. Lancaster MA, Renner M, Martin C-A, et al. Cerebral orga-
noids model human brain development and microcephaly.
Nature 2013;501:373–9.
54. Spence JR, Mayhew CN, Rankin SA, et al. Directed differ-
entiation of human pluripotent stem cells into intestinal tissue
in vitro. Nature 2011;470:105–9.
55. Xia Y, Sancho-Martinez I, Nivet E, et al. The generation of
kidney organoids by differentiation of human pluripotent cells
to ureteric bud progenitor-like cells. Nat Protoc 2014;9:
2693–704.
56. Zhong X, Gutierrez C, Xue T, et al. Generation of three-
dimensional retinal tissue with functional photoreceptors
from human iPSCs. Nat Commun 2014;5:4047.
57. Tena JJ, Alonso ME, la Calle-Mustienes de E, et al. An
evolutionarily conserved three-dimensional structure in the
vertebrate Irx clusters facilitates enhancer sharing and cor-
egulation. Nat Commun 2011;2:310.Footnotes and Financial DisclosuresOriginally received: September 15, 2015.
Final revision: October 7, 2015.
Accepted: October 7, 2015.
Available online: October 24, 2015. Manuscript no. 2015-1616.1 Molecular Insight Research Foundation, Glendale, California.
2 Department of Ophthalmology and Visual Sciences, Stephen A. Wynn
Institute for Vision Research, University of Iowa, Iowa City, Iowa.17
Ophthalmology Volume 123, Number 1, January 20163 National Eye Clinic, Kennedy Center, Glostrup, Denmark, and Institute of
Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
4 Service d’Exploration de la vision et Neuro-ophtalmologie CHRU, Lille,
France.
5 University of Texas Health Science Center at Houston, Houston, Texas.
6 Byers Eye Institute, Stanford University School of Medicine, Palo Alto,
California.
7 The Pangere Center for Inherited Retinal Diseases, The Chicago Light-
house for People Who Are Blind or Visually Impaired, Chicago, Illinois.
8 Department of Ophthalmology and Vision Sciences, Programme of Ge-
netics and Genomic Medicine, The Hospital for Sick Children, University
of Toronto, Toronto, Ontario, Canada.
Financial Disclosure(s):
The author(s) have made the following disclosure(s): T.R.: Consultant 
University Department of Ophthalmology, Glostrup, Denmark.
N.U.: Employee of and owns stock  Illumina.
E.H.: Grants  McLaughlin Foundation, Mira Godard Research Fund, and
Department of Ophthalmology Research Fund.
J.C.F.: Board member of and has stock options  IDx LLC.18J.H.F.: Received institutional grants from Regeneron.
Author Contributions:
Conception and design: Small, Mullins, Tucker, Stone
Data collection: Small, DeLuca, Whitmore, Rosenberg, Silva-Garcia, Udar,
Puech, Garcia, Rice, Fishman, Héon, Folk, Streb, Haas, Wiley, Scheetz,
Fingert, Mullins, Tucker, Stone
Analysis and interpretation: Small, DeLuca, Whitmore, Rosenberg, Silva-
Garcia, Udar, Puech, Garcia, Rice, Fishman, Héon, Folk, Streb, Haas,
Wiley, Scheetz, Fingert, Mullins, Tucker, Stone
Obtained funding: Not applicable
Overall responsibility: Small, DeLuca, Whitmore, Mullins, Tucker, Stone
Abbreviations and Acronyms:
AMD¼ age-related macular degeneration; bp ¼ base pairs; DHS ¼ DNase
1 hypersensitivity site; iPSC ¼ induced pluripotent stem cell;
NCMD ¼ North Carolina macular dystrophy; 3D ¼ 3-dimensional.
Correspondence:
Edwin M. Stone, MD, PhD, The Stephen A. Wynn Institute for Vision
Research, 375 Newton Road, 4111 MERF, Iowa City, IA 52242. E-mail:
edwin-stone@uiowa.edu.
